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Background: Regenerative medicine using cell therapy offers a promising strategy for recovery of damaged myocardium. C-kit-positive cardiac 
stem cells (CSCs) alleviate myocardial dysfunction after ischemic injury. Use of human cells in animals generally requires immuno-suppression 
limiting the duration of observation. We examined the effect of autologous CSCs in a late phase model of chronic myocardial infarction (MI) to 
determine the long term effect of these cells on cardiac structure and function.
Methods: Thoracotomy for ligation of the proximal LAD and additional diagonal branches was performed in canines, and atrial biopsy was 
performed for isolation, expansion, and culture of CSCs. 6 weeks following these procedures, baseline cardiac MRI was performed, and CSCs (n=13) 
or vehicle (n=6) were delivered via epicardial injection at site of LAD ligation and within the body of the infarct (800,000 cells each). 6 months post 
treatment, repeat MRI was performed. Cell administration and MRI analysis were performed in blinded fashion. Data were analyzed using covariate 
adjusted change from baseline. 5 animals died prior to cell injection and 1 died post treatment (CSC group).
Results: Left ventricular systolic volume increased to a greater extent in control animals compared to CSC treated (Table).
Conclusions: Intramyocardial injection of autologous CSCs in a late phase model of chronic MI favorably impacts long term cardiac remodeling.
Measurement Group Baseline (6 wks) 6 mos p-value (vehicle vs. CSC)
LV end systolic volume (ml) Vehicle 50.3±7.5 75.1±13.0 0.005CSC 48.6±16.4 58.0±15.6
LV end diastolic volume (ml) Vehicle 78.1±12.5 101.1±17.4 0.053CSC 69.6±18.6 85.2±15.0
LVEF (%) Vehicle 35.1±7.7 25.7±6.4 0.086CSC 30.9±5.4 32.7±7.3
Infarct mass(gms) Vehicle 6.6±2.2 5.8±2.0 0.258CSC 5.7±1.7 4.4±1.6
